Wei Wei Chen - 06 Apr 2022 Form 4 Insider Report for LianBio (LIANY)

Reporting relationship: Director
Issuer ticker: LIANY
Reported as of: 06 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Apr 2022, 16:27:49 UTC
Next SEC filing: 23 Jun 2023
Source filing: View source filing
Reporting owner signature: By: /s/ Angela Chen, Attorney-in-Fact

Key filing fact

Wei Wei Chen filed Form 4 for LianBio (LIANY) on 08 Apr 2022.

Key facts

This page summarizes Wei Wei Chen's Form 4 filing for LianBio (LIANY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Apr 2022, 16:27.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LIAN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +72,600
Change %
Price: $0.000000
Shares after: 72,600
Date: 06 Apr 2022
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 72,600
Exercise price: $4.95
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/36 of the shares underlying the option will become exercisable on 05/06/2022; the remainder shall vest and become exercisable in 35 equal monthly installments such that the option shall be fully vested on 04/06/2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.